Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. [PDF]
Cell Rep Med, 2022 Sharpe BP +24 more
europepmc +2 more sources
Why humans need type 5 phosphodiesterase inhibitors [PDF]
International Journal of Andrology, 2005 SummaryErectile dysfunction (ED) is a widespread medical condition affecting millions of males at any age and requiring medical treatment. ED may simply reflect a limit of human physiology, yet ED equates to genetic death and the high prevalence of ED is a clear evolutionary paradox.
CELLERINO, Alessandro, JANNINI E. A.
openaire +3 more sources
Toxins, 2023 Intracavernosal injections of botulinum toxin A (BTX/A ic) may be effective for difficult-to-treat erectile dysfunction (ED). This is a retrospective case series study of the effectiveness of repeated off-label BTX/A ic (onabotulinumtoxinA 100U ...
François Giuliano +2 more
doaj +1 more source
Phosphodiesterase Inhibitors: Present and Future
Barcelona Respiratory Network Reviews, 2023 Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj +1 more source
Cardiovascular Effects of Phosphodiesterase Type 5 Inhibitors
The Journal of Sexual Medicine, 2009 ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an increasing understanding of cyclic guanosine monophosphate (cGMP)-regulated mechanisms have triggered a number of attempts to
Charalambos, Vlachopoulos +3 more
openaire +4 more sources
The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review. [PDF]
, 2017 Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension.
Barrick, TR +6 more
core +1 more source
Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes [PDF]
, 2015 Endothelial dysfunction (ED) plays a role in diabetic cardiovascular complications. Hyperglycemia increases cytockines involved in vascular inflammation.
Bertolini, Camilla +10 more
core +1 more source
COVID-19 and phosphodiesterase enzyme type 5 inhibitors
Journal of Microscopy and Ultrastructure, 2020 COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension;
Al-Kuraishy, Hayder M. +5 more
openaire +3 more sources
Phosphodiesterase type 5 Inhibitors (PDE-5I) as a potential therapeutic drug in stroke: A systematic narrative review [PDF]
Romanian Journal of Neurology, 2023 Objectives. Stroke is an acute cerebrovascular disease with high morbidity and mortality rate. Many stroke management strategies can improve prognosis and quality of life, but only to a certain extent.
Harvey Sudharta +5 more
doaj +1 more source
The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. [PDF]
, 2013 The specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to decrease inflammation by suppression of pro-inflammatory cytokine synthesis.
A Hatzelmann +43 more
core +4 more sources